这篇文章不错，转发给_老虎社区_美港股上老虎 - 老虎社区

点赞
评论
收藏

june577
2020-09-12

这篇文章不错，转发给大家看看

奥本海默：核心业务以较高的个位数增长上调吉利德科学(GILD.US)目标价至105美元

智通财经网智通财经APP获悉，奥本海默（Oppenheimer）将吉利德科学(GILD.US)目标价从90美元上调至105美元，维持“跑赢大盘”评级。该行分析师Hartaj Singh表示，吉利德科学

奥本海默：核心业务以较高的个位数增长上调吉利德科学(GILD.US)目标价至105美元

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

点赞

举报

评论

推荐
最新

empty

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":976750958,"tweetId":"976750958","gmtCreate":1599873937974,"gmtModify":1703819966309,"author":{"id":3552733827063533,"idStr":"3552733827063533","authorId":3552733827063533,"authorIdStr":"3552733827063533","name":"june577","avatar":"https://static.tigerbbs.com/0b4a73631568940297a594271b3ab4c2","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>这篇文章不错，转发给大家看看</p></body></html>","htmlText":"<html><head></head><body><p>这篇文章不错，转发给大家看看</p></body></html>","text":"这篇文章不错，转发给大家看看","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/976750958","repostId":2066744220,"repostType":2,"repost":{"id":"2066744220","kind":"news","pubTimestamp":1599744120,"share":"https://www.laohu8.com/m/news/2066744220?lang=&edition=full","pubTime":"2020-09-10 21:22","market":"us","language":"zh","title":"奥本海默：核心业务以较高的个位数增长 上调吉利德科学(GILD.US)目标价至105美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2066744220","media":"智通财经网","summary":"智通财经网智通财经APP获悉，奥本海默（Oppenheimer）将吉利德科学(GILD.US)目标价从90美元上调至105美元，维持“跑赢大盘”评级。该行分析师Hartaj Singh表示，吉利德科学","content":"<html><body><article><p>智通财经网</p><p>智通财经APP获悉，奥本海默（Oppenheimer）将<a href=\"https://laohu8.com/S/GILD\">吉利德科学</a>(GILD.US)目标价从90美元上调至105美元，维持“跑赢大盘”评级。</p><p>该行分析师Hartaj Singh表示，吉利德科学目前股息率约为4%，其业务处于较为理想的状态，艾滋病毒领域的核心业务正以较高的个位数增长，而丙型肝炎病毒领域的业务稳定发展。</p><p>Hartaj Singh还认为，公司近期管线项目包括瑞德西韦、非戈替尼和单克隆抗体magrolimab提供了前瞻性，若整合到分析模型，预计吉利德未来3-5年的收入复合年增长率提高到约9%-10%，在同行中表现是最好的。</p><p>截至发稿，吉利德科学盘前涨1.12%，报65.23美元。</p></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>奥本海默：核心业务以较高的个位数增长 上调吉利德科学(GILD.US)目标价至105美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n奥本海默：核心业务以较高的个位数增长 上调吉利德科学(GILD.US)目标价至105美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-09-10 21:22 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202009102124367a177b54&s=b><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经网智通财经APP获悉，奥本海默（Oppenheimer）将吉利德科学(GILD.US)目标价从90美元上调至105美元，维持“跑赢大盘”评级。该行分析师Hartaj Singh表示，吉利德科学目前股息率约为4%，其业务处于较为理想的状态，艾滋病毒领域的核心业务正以较高的个位数增长，而丙型肝炎病毒领域的业务稳定发展。Hartaj Singh还认为，公司近期管线项目包括瑞德西韦、非戈替尼和...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202009102124367a177b54&s=b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/3c6daacf13f78492ec38a4e178ddca49","relate_stocks":{"GILD":"吉利德科学"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202009102124367a177b54&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2066744220","content_text":"智通财经网智通财经APP获悉，奥本海默（Oppenheimer）将吉利德科学(GILD.US)目标价从90美元上调至105美元，维持“跑赢大盘”评级。该行分析师Hartaj Singh表示，吉利德科学目前股息率约为4%，其业务处于较为理想的状态，艾滋病毒领域的核心业务正以较高的个位数增长，而丙型肝炎病毒领域的业务稳定发展。Hartaj Singh还认为，公司近期管线项目包括瑞德西韦、非戈替尼和单克隆抗体magrolimab提供了前瞻性，若整合到分析模型，预计吉利德未来3-5年的收入复合年增长率提高到约9%-10%，在同行中表现是最好的。截至发稿，吉利德科学盘前涨1.12%，报65.23美元。","news_type":1,"symbols_score_info":{"GILD":1}},"isVote":1,"tweetType":1,"viewCount":2491,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":27,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}